Search
Food allergy affects families' quality of life, can be lifelong and life-threatening, urging the identification of early modifiable risk factors. Formula feeding in the first days of life may increase the risk of cow's milk allergy, a risk often attributed to cow's milk allergens exposure. Early formula feeding also reduces the colostrum intake, the first 3 days' milk, which is rich in bioactive compounds critical for immune and gut health. This study investigates whether partial colostrum feeding increases the risk of food allergy beyond cow's milk.
The BioMood project will study how following a Mediterranean diet during pregnancy affects the gut microbiome, metabolism, and inflammation, with the expectation that it will promote a healthier microbiome and better mental health.
What if researchers could shop for different data to help uncover how, when and why chronic conditions such as asthma, obesity, allergies and poor mental health develop?
At The Kids Research Institute Australia, we have a dedicated and diverse team of over 1,000 staff, students and honorary researchers.
Research data from more than one million Australian and Welsh children will be examined to help better understand how the built environment affects child health and obesity, as part of an international research project to be co-led by The Kids Research Institute Australia.
First-of-its-kind findings show that newborns exclusively fed colostrum in their first 72 hours of life were five times less likely to develop a peanut allergy by 12-18 months, and 11 times less likely to develop multiple food allergies (such as egg or cow’s milk) compared with infants who also received formula
ORIGINS, the largest longitudinal cohort study of its kind in Australia, delivered in partnership between The Kids Research Institute Australia and Joondalup Health Campus, has received $1.5 million funding from the Minderoo Foundation.
The WA Kids Cancer Centre brings together clinicians and researchers working together to defeat childhood cancer.
Researchers have identified key differences between cancers that respond to immunotherapy and those that do not.
Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today